GSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

Investing.com -- GSK Plc的首席执行官Emma ...

Investing.com -- 英国制药公司GSK周一宣布，计划以高达11.5亿美元收购总部位于波士顿的生物制药公司IDRx。此举是GSK持续加强其在胃肠道癌症领域产品组合的一部分。 错过一次，就可能与财富翻倍的机会擦肩而过！用ProPicks，提前布局，6种AI选股模型助你今年的投资大放异彩！

Boston-based biotechnology firm developing therapy for treatment of gastrointestinal stromal tumors - Anadolu Ajansı ...

The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...

Under the agreement, GSK will pay $1billion upfront to acquire the Massachussetts-based firm, followed by up to $150million ...

Hallucinations are a persistent problem in healthcare. Here's how GSK is using test-time compute scaling to improve its gen AI systems.

IDRx’s lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal ...

The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.